Represents a Key Step Toward Validating Gedeptin Potential in Solid Tumor Therapy ATLANTA, GA - (NEWMEDIAWIRE) - GeoVax Labs, ...

GeoVax Labs (GOVX) announced significant progress in advancing Gedeptin as a cancer therapy. Gedeptin, based on a Gene-Directed Enzyme Prodrug ...

Dodd added, “In addition to our work with MUC1, our lead program in oncology is the development of Gedeptin®, a novel patented product for the treatment of solid tumors which recently completed ...

GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and ...

The Phase 1b/2a trial evaluated the safety and efficacy of repeat cycles of Gedeptin therapy in patients with advanced head and neck squamous cell carcinoma (HNSCC), with tumor(s) accessible for ...

EQS-News: GeoVax, Inc. / Key word (s): Financial GeoVax Announces Major Gedeptin Milestone With Plans of Phase 2 Trial 15.01.2025 / 15:05 CET/CEST The issuer is solely responsible for the content ...

Dodd added, “In addition to our work with MUC1, our lead program in oncology is the development of Gedeptin ®, a novel patented product for the treatment of solid tumors which recently completed a ...

Dodd added, "In addition to our work with MUC1, our lead program in oncology is the development of Gedeptin ®, a novel patented product for the treatment of solid tumors which recently completed ...